131-I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma

嗜铬细胞瘤是由肾上腺髓质或交感神经节细胞发展而来的神经内分泌肿瘤。这些肿瘤大多是良性的，但10%到30%是恶性的，预期寿命在3到5年之间。除了手术治疗局部疾病外，目前还没有已知的治疗恶性嗜铬细胞瘤的方法。目前广泛转移性疾病的治疗方法包括化疗、化学栓塞术、奥曲肽和131I-MIBG。总的来说，这些治疗是姑息性的，但很少有患者完全缓解。 本项目测试了131I-MIBG治疗恶性嗜铬细胞瘤的放射毒性疗效，特别是测试了使用特定药物(即所谓的增敏剂)进行预治疗是否会增加131I-MIBG治疗的疗效。最近，为了找到能为我们提供131I-MIBG的实验室，协议被搁置了。

Pheochromocytomas are neuroendocrine tumors that develop from cells in the adrenal medulla or sympathetic ganglion. Most of these tumors are benign but 10 to 30% are malignant with life expectancy ranging 3 to 5 years. Other than surgery for local disease, there is no known curative treatment for malignant pheochromocytoma. Current therapies for widespread metastatic disease include chemotherapy, chemoembolization, octreotide, and 131I-MIBG. In general these treatments are palliative but very few patients have had complete responses This project tests the efficacy of radiotoxic treatment of malignant pheochromocytoma using 131I-MIBG, and in particular tests whether pre-treatment using specific drugs (so called sentitizers) increases the efficacy of 131I-MIBG treatment. Recently, the protocol has been on hold to find a laboratory that will supply us with 131I-MIBG.